Financial Analysis: Annovis Bio (NYSE:ANVS) and Amneal Pharmaceuticals (NASDAQ:AMRX)

Amneal Pharmaceuticals (NASDAQ:AMRX – Get Free Report) and Annovis Bio (NYSE:ANVS – Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings.

Insider and Institutional Ownership

31.8% of Amneal Pharmaceuticals shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 26.6% of Amneal Pharmaceuticals shares are held by insiders. Comparatively, 38.3% of Annovis Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Amneal Pharmaceuticals and Annovis Bio, as provided by MarketBeat.com.

Amneal Pharmaceuticals currently has a consensus target price of $9.40, suggesting a potential upside of 14.77%. Annovis Bio has a consensus target price of $33.60, suggesting a potential upside of 261.29%. Given Annovis Bio’s stronger consensus rating and higher probable upside, analysts plainly believe Annovis Bio is more favorable than Amneal Pharmaceuticals.

Profitability

This table compares Amneal Pharmaceuticals and Annovis Bio’s net margins, return on equity and return on assets.

Volatility and Risk

Amneal Pharmaceuticals has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Annovis Bio has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500.

Valuation and Earnings

This table compares Amneal Pharmaceuticals and Annovis Bio”s top-line revenue, earnings per share (EPS) and valuation.

Annovis Bio has lower revenue, but higher earnings than Amneal Pharmaceuticals. Amneal Pharmaceuticals is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Summary

Annovis Bio beats Amneal Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Amneal Pharmaceuticals

(Get Free Report)

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

About Annovis Bio

(Get Free Report)

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.